当前位置: 首页 > 详情页

Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Interventional Radiology, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215001, China [2]Department of Burn Surgery, The Linyi People’s Hospital, Linyi 276000, China [3]Department of Radiotherapy, Hubei Cancer Hospital, Wuhan 430000, China [4]Department of Hand and Foot Surgery, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215001, China
出处:
ISSN:

关键词: Hepatocellular carcinoma Cinobufotalin Apoptosis SphK1 and ceramide

摘要:
Hepatocellular carcinoma (HCC) is a highly aggressive and lethal neoplasm with poor prognosis. The aim of this study is to investigate the anticancer activity of cinobufotalin, a bufadienolide isolated from toad venom, in cultured HCC cells, and to study the underlying mechanisms. We found that cinobufotalin (at nmol/L) significantly inhibited HCC cell growth and survival while inducing considerable cell apoptosis. Further, cinobufotalin inhibited sphingosine kinase 1 (SphK1) activity and induced pro-apoptotic ceramide production. Ceramide synthase-1 small hairpin RNA (shRNA)-depletion inhibited cinobufotalin-induced ceramide production and HCC cell apoptosis. On the other hand, the glucosylceramide synthase (GCS) inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitated cinobufotalin-induced ceramide production and cell apoptosis. SphK1 inhibitor II (SKI-II), similar to cinobufotalin, increased cellular ceramide level and promoted HCC cell apoptosis. Finally, we observed that cinobufotalin inactivated Akt-S6K1 signaling in HepG2 cells, which was again inhibited by ceramide synthase-1 shRNA-depletion. In conclusion, the results of this study suggest that cinobufotalin induces growth inhibition and apoptosis in cultured HCC cells through ceramide production. Cinobufotalin may be investigated as a novel anti-HCC agent.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2013]版:
Q2 ONCOLOGY
最新[2024]版:

影响因子: 最新[2024版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Department of Interventional Radiology, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215001, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Interventional Radiology, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215001, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:18243 今日访问量:0 总访问量:1002 更新日期:2025-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院